NCT03190616 is a Phase 2 clinical trial of apatinib in Colorectal Neoplasms, sponsored by The First Affiliated Hospital with Nanjing Medical University.

Who is sponsoring NCT03190616?

NCT03190616 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What drugs are being tested in NCT03190616?

Interventions in NCT03190616: apatinib.

What condition does NCT03190616 study?

NCT03190616 studies Colorectal Neoplasms.

Is NCT03190616 still recruiting?

NCT03190616 is currently completed. Last updated 14 January 2020.

Last reviewed 2020-01-14 · How we verify

NCT03190616

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apatinib in Refractory Colorectal Cancer

Completed Phase 2 Last updated 14 January 2020

What this trial tests

Phase 2 trial testing apatinib in Colorectal Neoplasms in 54 participants. Completed in 30 December 2019.

Timeline

1 July 2017

Primary endpoint
30 June 2019

30 December 2019

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	1 July 2017
Primary completion	30 June 2019
Estimated completion	30 December 2019
Sites	4 locations across China

Drugs / interventions tested

apatinib (Apatinib) — full drug profile →

Conditions studied

Colorectal Neoplasms — all drugs for Colorectal Neoplasms →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

18 and older, any sex, with Colorectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Limited agents have been approved after standard first and second line treatment. Regorafenib and Trifluridine/Tipiracil (TAS-102) are still not approved in China.Apatinib has shown significant efficacy in refractory advanced gastric cancer regarding PFS and OS with controllable toxicity.This study is aimed to explore the efficacy,safety as well as predictive biomarker in advanced colorectal cancer failed to standard therapy in Chinese population.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond.
Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. · · 2023 · cited 53× · PMID 36998426 · DOI 10.3748/wjg.v29.i9.1395
The role of tumor angiogenesis as a therapeutic target in colorectal cancer.
Battaglin F, Puccini A, Intini R, Schirripa M, et al · · 2018 · cited 48× · PMID 29338550 · DOI 10.1080/14737140.2018.1428092
A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
Chen X, Qiu T, Zhu Y, Sun J, et al · · 2019 · cited 43× · PMID 30877190 · DOI 10.1634/theoncologist.2019-0164
Colorectal Cancer: From Genetic Landscape to Targeted Therapy.
El Bali M, Bakkach J, Bennani Mechita M. · · 2021 · cited 29× · PMID 34326875 · DOI 10.1155/2021/9918116
Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018.
Shahjehan F, Kamatham S, Kasi PM. · · 2019 · cited 10× · PMID 31139561 · DOI 10.3389/fonc.2019.00358
Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges.
Matsuoka T, Yashiro M. · · 2021 · cited 7× · PMID 34040699 · DOI 10.4251/wjgo.v13.i5.366
Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication.
Han Y, Zhu B, Meng S. · · 2025 · cited 6× · PMID 40821121 · DOI 10.1016/j.gendis.2025.101611
Fruquintinib effectively controlled the advanced small bowel adenocarcinoma progressed after multiple lines of palliative treatment: a case report and literature review.
Ding Y, Wang J, Zhu N, Xu D, et al · · 2020 · cited 1× · PMID 33151122 · DOI 10.1080/15384047.2020.1836549

Verify or expand the search:

Other trials of apatinib

Trials testing the same drug.

NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT05699655 — Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann I · Phase 2, PHASE3 · recruiting
NCT04824352 — Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma · Phase 2 · suspended
NCT04720131 — Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. · Phase 2 · completed
NCT04014101 — SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma · Phase 2 · unknown

Other recruiting trials for Colorectal Neoplasms

Currently open trials in the same condition.

NCT06983639 — Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance · NA · recruiting
NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
NCT07239479 — DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy · NA · recruiting
NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
NCT07257653 — The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line · Phase 2 · recruiting

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03190616 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 14 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03190616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing